BioPharmSignal logoBioPharmSignal

Biotech News

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

Sensei Biotherapeutics (SNSE)Sensei BiotherapeuticsEarnings

BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter 2025.

Related news

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

GNLXGenelux2026-08-13 20:20 EST

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

MGNXMacroGenics2026-08-13 20:05 EST

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

INBXInhibrx2026-08-13 20:04 EST

Inhibrx Reports Second Quarter 2026 Financial Results

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

View all latest news

Sensei Biotherapeutics

Sensei Biotherapeutics is an immuno-oncology company focused on activating the immune system against cancer. Its platform aims to create differentiated cancer treatments through immune modulation.

Recent company news

SNSESensei Biotherapeutics2026-05-15 11:30 EST

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

SNSESensei Biotherapeutics2026-05-05 11:30 EST

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

SNSESensei Biotherapeutics2026-04-09 11:30 EST

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

SNSESensei Biotherapeutics2026-03-30 11:30 EST

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

SNSESensei Biotherapeutics2026-03-17 10:00 EST

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
13.85 USD
Market cap
21.6M USD
Exchange
NYSE
Sector
Biopharma
Location
United States